<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d52">
    <sentence id="DDI-DrugBank.d52.s0" text="Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation">
        <entity id="DDI-DrugBank.d52.s0.e0" charOffset="27-39"
            type="group" text="thrombolytics"/>
        <entity id="DDI-DrugBank.d52.s0.e1" charOffset="55-67"
            type="drug" text="streptokinase"/>
        <entity id="DDI-DrugBank.d52.s0.e2" charOffset="158-165"
            type="brand" text="REFLUDAN"/>
        <pair id="DDI-DrugBank.d52.s0.p0" e1="DDI-DrugBank.d52.s0.e0"
            e2="DDI-DrugBank.d52.s0.e1" ddi="false"/>
        <pair id="DDI-DrugBank.d52.s0.p1" e1="DDI-DrugBank.d52.s0.e0"
            e2="DDI-DrugBank.d52.s0.e2" ddi="false"/>
        <pair id="DDI-DrugBank.d52.s0.p2" e1="DDI-DrugBank.d52.s0.e1"
            e2="DDI-DrugBank.d52.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d52.s1" text="Concomitant treatment with coumarin derivatives (vitamin K antagonists) and drugs that affect platelet function may also increase the risk of bleeding.">
        <entity id="DDI-DrugBank.d52.s1.e0" charOffset="27-46"
            type="group" text="coumarin derivatives"/>
        <entity id="DDI-DrugBank.d52.s1.e1" charOffset="49-69"
            type="group" text="vitamin K antagonists"/>
        <pair id="DDI-DrugBank.d52.s1.p0" e1="DDI-DrugBank.d52.s1.e0"
            e2="DDI-DrugBank.d52.s1.e1" ddi="false"/>
    </sentence>
</document>
